Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Trasylol

- PMLiVE

EMA defends position on patient-level data

Regulator claims pharma industry fears over transparency are unfounded

- PMLiVE

Ariad tanks as Iclusig trial is halted on safety grounds

Shares fall after leukaemia patients develop blood clots

- PMLiVE

Communications rethink for Health Canada

Government review of regulator’s outreach efforts follows recall of birth-control drug

- PMLiVE

J&J files HIV combination in Europe

Seeks approval for fixed-dose tablet containing Prezista and Gilead’s cobicistat

- PMLiVE

IQWiG: Key data missing from public trial reports

German HTA body claims drug studies published in journals contain ”insufficient information"

- PMLiVE

Ariad halts patient enrolment for cancer drug studies

Concerns raised after patients taking Iclusig experience blood clots and cardiovascular events

EU flag

Pharmacists back trial transparency in Europe

European Association of Hospital Pharmacist supports EMA’s plans to improve access to study results

- PMLiVE

Translational pharmacology and drug dosing

The key to ensuring safe and effective dosing

- PMLiVE

Orexigen files obesity drug in EU

Company expects Contrave to show positive cardiovascular safety 

- PMLiVE

EU launches black triangle drug monitoring scheme

New pharmacovigilance symbol will be used by all drugs needing additional monitoring

- PMLiVE

AZ moves closer to EU approval for ovarian cancer drug

Olaparib on course to be first PARP inhibitor available for ovarian cancer

- PMLiVE

EASD 2013: Sanofi justifies decision to withdraw US filing for Lyxumia

Takes issue with FDA's narrow risk-benefit focus

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links